These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 32819590)

  • 1. GDC-0980 (apitolisib) treatment with gemcitabine and/or cisplatin synergistically reduces cholangiocarcinoma cell growth by suppressing the PI3K/Akt/mTOR pathway.
    Jang DK; Lee YG; Chan Chae Y; Lee JK; Paik WH; Lee SH; Kim YT; Ryu JK
    Biochem Biophys Res Commun; 2020 Sep; 529(4):1242-1248. PubMed ID: 32819590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the PI3K/AKT/mTOR pathway offer a promising therapeutic strategy for cholangiocarcinoma patients with high doublecortin-like kinase 1 expression.
    Liang Z; Ge Y; Li J; Bai Y; Xiao Z; Yan R; An G; Zhang D
    J Cancer Res Clin Oncol; 2024 Jul; 150(7):342. PubMed ID: 38980538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A PLCB1-PI3K-AKT Signaling Axis Activates EMT to Promote Cholangiocarcinoma Progression.
    Liang S; Guo H; Ma K; Li X; Wu D; Wang Y; Wang W; Zhang S; Cui Y; Liu Y; Sun L; Zhang B; Xin M; Zhang N; Zhou H; Liu Y; Wang J; Liu L
    Cancer Res; 2021 Dec; 81(23):5889-5903. PubMed ID: 34580062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased activation of PI3K/AKT signaling pathway is associated with cholangiocarcinoma metastasis and PI3K/mTOR inhibition presents a possible therapeutic strategy.
    Yothaisong S; Dokduang H; Techasen A; Namwat N; Yongvanit P; Bhudhisawasdi V; Puapairoj A; Riggins GJ; Loilome W
    Tumour Biol; 2013 Dec; 34(6):3637-48. PubMed ID: 23832540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasmalemma vesicle-associated protein promotes angiogenesis in cholangiocarcinoma via the DKK1/CKAP4/PI3K signaling pathway.
    Wang Y; Yu H; Xie X; Deng T; Ye L; Wu L; Ding X; Yang Z; Zhu Q; Li J; Zheng Y; Yu Z; Chen G
    Oncogene; 2021 Jun; 40(25):4324-4337. PubMed ID: 34079085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of FGFR2 enhances chemosensitivity to gemcitabine in cholangiocarcinoma through the AKT/mTOR and EMT signaling pathways.
    Jaidee R; Kukongviriyapan V; Senggunprai L; Prawan A; Jusakul A; Laphanuwat P; Kongpetch S
    Life Sci; 2022 May; 296():120427. PubMed ID: 35218764
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Knockdown of tripartite motif 59 (TRIM59) inhibits proliferation in cholangiocarcinoma via the PI3K/AKT/mTOR signalling pathway.
    Shen H; Zhang J; Zhang Y; Feng Q; Wang H; Li G; Jiang W; Li X
    Gene; 2019 May; 698():50-60. PubMed ID: 30822475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor activity of the combination of an HSP90 inhibitor and a PI3K/mTOR dual inhibitor against cholangiocarcinoma.
    Chen MH; Chiang KC; Cheng CT; Huang SC; Chen YY; Chen TW; Yeh TS; Jan YY; Wang HM; Weng JJ; Chang PM; Liu CY; Li CP; Chao Y; Chen MH; Huang CY; Yeh CN
    Oncotarget; 2014 May; 5(9):2372-89. PubMed ID: 24796583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway.
    Wallin JJ; Edgar KA; Guan J; Berry M; Prior WW; Lee L; Lesnick JD; Lewis C; Nonomiya J; Pang J; Salphati L; Olivero AG; Sutherlin DP; O'Brien C; Spoerke JM; Patel S; Lensun L; Kassees R; Ross L; Lackner MR; Sampath D; Belvin M; Friedman LS
    Mol Cancer Ther; 2011 Dec; 10(12):2426-36. PubMed ID: 21998291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Everolimus regulates the activity of gemcitabine-resistant pancreatic cancer cells by targeting the Warburg effect via PI3K/AKT/mTOR signaling.
    Cui J; Guo Y; Wu H; Xiong J; Peng T
    Mol Med; 2021 Apr; 27(1):38. PubMed ID: 33849427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined targeting of AKT and mTOR using MK-2206 and RAD001 is synergistic in the treatment of cholangiocarcinoma.
    Ewald F; Grabinski N; Grottke A; Windhorst S; Nörz D; Carstensen L; Staufer K; Hofmann BT; Diehl F; David K; Schumacher U; Nashan B; Jücker M
    Int J Cancer; 2013 Nov; 133(9):2065-76. PubMed ID: 23588885
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-Tumor and Chemosensitizing Effects of the CDK Inhibitor Dinaciclib on Cholangiocarcinoma
    Sungwan P; Kidoikhammouan S; Thonsri U; Saengboonmee C; Wongkham S; Okada S; Seubwai W
    In Vivo; 2024; 38(5):2284-2293. PubMed ID: 39187317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor activity of celastrol by inhibition of proliferation, invasion, and migration in cholangiocarcinoma via PTEN/PI3K/Akt pathway.
    Zhu B; Wei Y
    Cancer Med; 2020 Jan; 9(2):783-796. PubMed ID: 31957323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel Dual PI3K/mTOR Inhibitor, Apitolisib (GDC-0980), Inhibits Growth and Induces Apoptosis in Human Glioblastoma Cells.
    Omeljaniuk WJ; Krętowski R; Ratajczak-Wrona W; Jabłońska E; Cechowska-Pasko M
    Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic antiproliferative effects of an mTOR inhibitor (rad001) plus gemcitabine on cholangiocarcinoma by decreasing choline kinase activity.
    Lin G; Lin KJ; Wang F; Chen TC; Yen TC; Yeh TS
    Dis Model Mech; 2018 May; 11(8):. PubMed ID: 29666220
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MET and PI3K/mTOR as a potential combinatorial therapeutic target in malignant pleural mesothelioma.
    Kanteti R; Dhanasingh I; Kawada I; Lennon FE; Arif Q; Bueno R; Hasina R; Husain AN; Vigneswaran W; Seiwert T; Kindler HL; Salgia R
    PLoS One; 2014; 9(9):e105919. PubMed ID: 25221930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel PI3K/mTOR dual inhibitor, CMG002, overcomes the chemoresistance in ovarian cancer.
    Choi HJ; Heo JH; Park JY; Jeong JY; Cho HJ; Park KS; Kim SH; Moon YW; Kim JS; An HJ
    Gynecol Oncol; 2019 Apr; 153(1):135-148. PubMed ID: 30686552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma.
    Powles T; Lackner MR; Oudard S; Escudier B; Ralph C; Brown JE; Hawkins RE; Castellano D; Rini BI; Staehler MD; Ravaud A; Lin W; O'Keeffe B; Wang Y; Lu S; Spoerke JM; Huw LY; Byrtek M; Zhu R; Ware JA; Motzer RJ
    J Clin Oncol; 2016 May; 34(14):1660-8. PubMed ID: 26951309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Compound C induces protective autophagy in human cholangiocarcinoma cells via Akt/mTOR-independent pathway.
    Zhao X; Luo G; Cheng Y; Yu W; Chen R; Xiao B; Xiang Y; Feng C; Fu W; Duan C; Yao F; Xia X; Tao Q; Wei M; Dai R
    J Cell Biochem; 2018 Jul; 119(7):5538-5550. PubMed ID: 29384220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The combination of gemcitabine plus an anti-FGFR inhibitor can have a synergistic antitumor effect on FGF-activating cholangiocarcinoma.
    Ito Y; Yamada D; Kobayashi S; Sasaki K; Iwagami Y; Tomimaru Y; Asaoka T; Noda T; Takahashi H; Shimizu J; Doki Y; Eguchi H
    Cancer Lett; 2024 Jul; 595():216997. PubMed ID: 38801887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.